Please check your internet connection and try again.
# Meftal spas
## Overview
Meftal spas is a combination product containing mefenamic acid, a nonsteroidal anti-inflammatory drug (NSAID), and dicyclomine, an anticholinergic antispasmodic agent.
## Primary Indications
* Relief of abdominal pain and cramps associated with irritable bowel syndrome (IBS) and other gastrointestinal disorders.
* Management of dysmenorrhea.
## Adult Dosing
* **Irritable Bowel Syndrome/Gastrointestinal Disorders:** 1 tablet (containing mefenamic acid 250 mg and dicyclomine hydrochloride 20 mg) three times daily, typically taken before meals. Maximum daily dose is not explicitly defined for the combination product but consider individual component maximums (mefenamic acid: 1500 mg/day, dicyclomine: 80 mg/day).
* **Dysmenorrhea:** 1 tablet three times daily, starting at the onset of pain. Duration of use is typically limited to the period of painful menstruation.
## Pediatric Dosing
Dosing for pediatric patients has not been established for Meftal spas. Mefenamic acid is generally not recommended for use in children under 12 years of age due to potential risks.
## Dose Adjustments
* **Renal Impairment:** Mefenamic acid should be used with caution in patients with renal impairment. Use in severe renal impairment is generally contraindicated.
* **Hepatic Impairment:** Mefenamic acid should be used with caution in patients with hepatic impairment. Use in severe hepatic impairment is generally contraindicated.
* **Elderly:** Elderly patients are more susceptible to NSAID-related adverse effects, including gastrointestinal bleeding and renal dysfunction. Use with caution and at the lowest effective dose.
## Contraindications
* Hypersensitivity to mefenamic acid, dicyclomine, or any component of the formulation.
* History of asthma, urticaria, or allergic-type reactions after aspirin or other NSAIDs.
* Inflammatory bowel disease.
* Gastrointestinal obstruction or bleeding.
* Myasthenia gravis.
* Glaucoma.
* Uncontrolled heart failure.
* Severe renal or hepatic impairment.
* Children under 12 years of age (for mefenamic acid component).
## Adverse Effects
**Common:**
* Gastrointestinal: Nausea, vomiting, diarrhea, constipation, abdominal pain, dyspepsia.
* Central Nervous System: Dizziness, headache, drowsiness.
* Anticholinergic (from dicyclomine): Dry mouth, blurred vision, urinary retention, constipation.
**Serious:**
* Gastrointestinal: Ulceration, perforation, bleeding.
* Cardiovascular: Increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke.
* Renal: Renal papillary necrosis and other renal injury.
* Hepatic: Jaundice, hepatic failure.
* Hypersensitivity reactions: Anaphylaxis, severe skin reactions.
## Key Drug Interactions
* **Other NSAIDs, Aspirin:** Increased risk of gastrointestinal bleeding and ulceration.
* **Anticoagulants (e.g., warfarin):** Increased risk of bleeding.
* **Corticosteroids:** Increased risk of gastrointestinal bleeding.
* **Diuretics, ACE Inhibitors, ARBs:** NSAIDs can reduce the efficacy of these drugs and increase the risk of renal impairment.
* **Lithium:** NSAIDs can increase serum lithium levels.
* **SSRIs/SNRIs:** Increased risk of gastrointestinal bleeding.
* **Anticholinergic agents:** Additive anticholinergic effects with dicyclomine.
## Monitoring
* Monitor for signs and symptoms of gastrointestinal bleeding.
* Assess for signs of renal and hepatic dysfunction.
* Monitor blood pressure, especially in patients with cardiovascular risk factors.
* Evaluate for effectiveness and for adverse effects of both mefenamic acid and dicyclomine.
## Clinical Pearls
* Meftal spas combines an NSAID for pain and inflammation with an antispasmodic for smooth muscle relaxation, offering a dual mechanism for abdominal pain relief.
* Administer with food or milk to minimize gastrointestinal upset.
* Due to the anticholinergic effects of dicyclomine, caution is advised in patients with conditions exacerbated by anticholinergics (e.g., prostatic hypertrophy, certain cardiac conditions).
* The use of NSAIDs, including mefenamic acid, carries a risk of serious cardiovascular thrombotic events.
* The lowest effective dose should be used for the shortest duration necessary to control symptoms.
**Educational Disclaimer:** This information is intended for clinical use and is not a substitute for professional medical advice. Always consult the most current prescribing information and local institutional protocols for definitive guidance.
